Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 earnings following check-ins with investor relations teams and recent public commentary, the analyst tells investors in a preview for the group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Insulin prices have dropped but some poor patients are paying more, NYT says
- Eli Lilly price target lowered to $970 from $1,050 at Berenberg
- Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
- Eli Lilly Q4 miss brings buying opportunity, says JPMorgan
- Leerink remains bullish on Eli Lilly despite lower Q4 revenue guidance